This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

1. (Previously Presented) A compound of Formula I

$$\begin{array}{c|c}
R^1 & H \\
\hline
 & 1 & 2 \\
\hline
 & 5 & 4 & 3 \\
R^2 & R^3 & Q & I
\end{array}$$


wherein A is O or S;

wherein Q is selected from -N(R<sup>5</sup>)<sub>2</sub>, -NR<sup>5</sup>C(O)R<sup>5</sup>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-OR<sup>5</sup>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-S(O)<sub>n</sub>R<sup>6</sup>,

so<sub>2</sub>R<sup>6</sup>, substituted aryl, an unsubstituted or substituted monocyclic or bicyclic, non-aromatic carbocyclic ring, an unsubstituted or substituted monocyclic or bicyclic, heteroaryl ring, and an unsubstituted or substituted monocyclic or bicyclic, non-aromatic heterocyclic ring,

wherein a ring is unsubstituted or substituted with one or more groups selected from halo,  $(C_1-C_8)$ alkyl,  $(C_2-C_8)$ alkynyl,  $(C_2-C_8)$ alkenyl,  $-OR^5$ ,  $-O-(CH_2)_{1\cdot2}-O-$ ,  $-N(R^5)_2$ ,  $-(C_1-C_8)$ alkyl- $N(R^5)_2$ ,  $(C_1-C_8)$ haloalkyl, lower cyanoalkyl,  $-(C_1-C_8)$ alkyl- $OR^5$ , lower alkylaminoalkoxy, lower aminoalkoxyalkyl,  $-(C_1-C_8)$ alkyl- $S(O)_nR^5$ ,  $-N(R^5)-(C_1-C_8)$ alkyl- $S(O)_nR^5$ ,  $-SO_2NR^5R^5$ ,  $-N(R^5)-(C_1-C_8)$ alkyl- $S(O)_nR^5$ , cyano, nitro, optionally substituted  $(C_3-C_10)$ cycloalkyl, optionally substituted aryl, optionally substituted 4-7 membered heterocyclyl, optionally substituted phenoxyalkyl, optionally substituted heterocyclyloxyalkyl,  $-C(O)N(R^5)_2$ ,  $-CO_2R^5$ ,  $-CO_2N(R^5)_2$ ,  $-SO_2NHC(O)R^5$ , optionally substituted phenylalkyl, optionally substituted heterocyclylalkyl,  $-N(R^5)_2$ ,  $-N(R^5)_2$ , -N(R

#### wherein W is selected from



wherein n is 0, 1 or 2;

wherein R<sup>1</sup> is selected from H, -OR<sup>6</sup>, halo, aryl, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>2</sub>-C<sub>8</sub>)alkenyl, (C<sub>2</sub>-C<sub>8</sub>)alkynyl, (C<sub>1</sub>-C<sub>8</sub>)perfluoroalkyl, -NR<sup>5</sup><sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-NR<sup>5</sup><sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-OR<sup>5</sup>, -S(O)<sub>n</sub>-alkyl, -S(O)<sub>n</sub>-aryl, -S(O)<sub>n</sub>-heteroaryl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, nitro, heterocyclyl, -NR<sup>5</sup>SO<sub>2</sub>R<sup>5</sup>, -C(O)N(R<sup>5</sup>)<sub>2</sub>, -CO<sub>2</sub>R<sup>5</sup>, -(CR<sup>5</sup><sub>2</sub>)<sub>1-8</sub>aryl, -(CR<sup>5</sup><sub>2</sub>)<sub>1-8</sub>heterocyclyl, -NR<sup>5</sup>C(O)N(R<sup>5</sup>)<sub>2</sub>, -NR<sup>5</sup>C(O)R<sup>5</sup>, -NR<sup>5</sup>CO<sub>2</sub>R<sup>5</sup>, and -C(O)R<sup>5</sup>; wherein R<sup>1</sup> and R<sup>2</sup> may be joined to form a 5-10 membered saturated or partially unsaturated carbocyclic or heterocyclic ring;

wherein R<sup>2</sup> is selected from H, -OR<sup>6</sup>, halo, aryl, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>2</sub>-C<sub>8</sub>)alkenyl, (C<sub>2</sub>-C<sub>8</sub>)alkynyl, (C<sub>1</sub>-C<sub>8</sub>)perfluoroalkyl, -NR<sup>5</sup><sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-NR<sup>5</sup><sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-OR<sup>5</sup>, -S(O)<sub>n</sub>-alkyl, -S(O)<sub>n</sub>-aryl, -S(O)<sub>n</sub>-heteroaryl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, nitro, heterocyclyl, -NR<sup>5</sup>SO<sub>2</sub>R<sup>5</sup>, -C(O)N(R<sup>5</sup>)<sub>2</sub>, -CO<sub>2</sub>R<sup>5</sup>, -(CR<sup>5</sup><sub>2</sub>)<sub>1-8</sub>aryl, -(CR<sup>5</sup><sub>2</sub>)<sub>1-8</sub>heterocyclyl, -NR<sup>5</sup>C(O)N(R<sup>5</sup>)<sub>2</sub>, -NR<sup>5</sup>C(O)R<sup>5</sup>, -NR<sup>5</sup>CO<sub>2</sub>R<sup>5</sup>, and -C(O)R<sup>5</sup>;

wherein R³ is selected from H, -OR6, halo, aryl, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>2</sub>-C<sub>8</sub>)alkenyl, (C<sub>2</sub>-C<sub>8</sub>)alkynyl, (C<sub>1</sub>-C<sub>8</sub>)perfluoroalkyl, -NR<sup>5</sup><sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-NR<sup>5</sup><sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-OR<sup>5</sup>, -S(O)<sub>n</sub>-alkyl, -S(O)<sub>n</sub>-aryl, -S(O)<sub>n</sub>-heteroaryl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, nitro, heterocyclyl, -NR<sup>5</sup>SO<sub>2</sub>R<sup>5</sup>, -C(O)N(R<sup>5</sup>)<sub>2</sub>, -CO<sub>2</sub>R<sup>5</sup>, -(CR<sup>5</sup><sub>2</sub>)<sub>1-8</sub>aryl, -(CR<sup>5</sup><sub>2</sub>)<sub>1-8</sub>heterocyclyl, -NR<sup>5</sup>C(O)N(R<sup>5</sup>)<sub>2</sub>, -NR<sup>5</sup>C(O)R<sup>5</sup>, -NR<sup>5</sup>CO<sub>2</sub>R<sup>5</sup>, and -C(O)R<sup>5</sup>; wherein R² and R³ may be joined to form a 5-10 membered saturated or partially unsaturated carbocyclic or heterocyclic ring;

wherein R<sup>4</sup> is independently selected from H, and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

wherein R<sup>5</sup> is independently selected from H, lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl-alkyl, lower alkylamino-lower alkyl, aryloxyalkyl, alkylcarbonylalkyl, and lower perfluoroalkyl; and

wherein R<sup>6</sup> is independently selected from lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl-alkyl, lower alkylamino-lower alkyl, aryloxyalkyl, alkylcarbonylalkyl, and lower perfluoroalkyl;

wherein each aryl, heteroaryl, cycloalkyl, and heterocyclyl moiety of any R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, and Q is optionally substituted with one or more groups selected from halo, -NH<sub>2</sub>, -OH, -CO<sub>2</sub>H, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxyalkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, phenyl, and heterocyclyl;

and pharmaceutically acceptable salts thereof;

provided R<sup>1</sup> is not CF<sub>3</sub> when R<sup>2</sup> is ethoxycarbonyl, when R<sup>3</sup> is H, when W is thiazol-4-yl and when Q is 4-pyridyl or 2-chloro-4-pyridyl; further provided Q is not 4-pyridyl, when W is thiazol-2-yl, when R<sup>1</sup>, R<sup>3</sup>, and R<sup>2</sup> are H; further provided Q is not 2-nitro-5-furyl when W is thiazol-2-yl, when R<sup>1</sup> is methyl, when R<sup>3</sup> is H, and when R<sup>2</sup> is H; further provided Q is not phenyl when W is thiazol-2-yl, when R<sup>1</sup> is methyl, when R<sup>3</sup> is methyl, and when R<sup>2</sup> is H; further provided Q is not phenyl, 3,4-diacetylphenyl or 3,4-dihydroxyphenyl, when W is thiazol-2-yl, when R<sup>1</sup> is H, when R<sup>3</sup> is H, and when R<sup>2</sup> is H; and further provided Q is not 3-cyano-6-methyl-2-oxo-1,2-dihydro-5-pyridyl, when W is thiazol-2-yl, when R<sup>1</sup> is methyl, when R<sup>3</sup> is H, and when R<sup>2</sup> is acetyl.

2. (Previously Presented) A Compound of Claim 1 wherein Q is selected from

$$R^6SO_2$$
-( $C_1$ - $C_6$ )alkyl-,  $R^4$  , substituted phenyl, and substituted or unsubstituted 5-6 membered heteroaryl;

wherein R<sup>4</sup> is independently selected from H, and (C<sub>1</sub>-C<sub>2</sub>)alkyl; and wherein R<sup>6</sup> is independently selected from (C<sub>1</sub>-C<sub>4</sub>)alkyl, optionally substituted phenyl, optionally substituted phenyl-(C<sub>1</sub>-C<sub>2</sub>)alkyl, optionally substituted furyl-(C<sub>1</sub>-C<sub>2</sub>)-alkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl-(C<sub>1</sub>-C<sub>2</sub>)-alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkylamino-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, phenyloxy-(C<sub>1</sub>-C<sub>3</sub>)alkyl-, (C<sub>1</sub>-C<sub>2</sub>)alkylcarbonyl-(C<sub>1</sub>-C<sub>2</sub>)alkyl- and optionally substituted heterocyclyl selected from pyridyl and thienyl; and pharmaceutically acceptable salts thereof.

3. (Previously Presented) A Compound of Claim 2 wherein Q is selected from phenylsulfonylamino, N-methyl-N-(2-pyridylsulfonyl)amino, N-methyl-N-(3-pyridylsulfonyl)amino, N-methyl-N-(4-pyridylsulfonyl)amino, N-methyl-N-(2-thienylsulfonyl)amino, N-methyl-N-(phenylsulfonyl)amino, 2-pyridylsulfonylmethyl, 3-pyridylsulfonylmethyl, 4-pyridylsulfonylmethyl, 2-thienylsulfonylmethyl, phenylsulfonylmethyl, (1-methyl)-1-(phenylsulfonyl)ethyl, 4-chlorophenyl-sulfonylmethyl, 2-furylmethylsulfonylmethyl, 3-trifluoromethylbenzyl-sulfonylmethyl, methylsulfonylmethyl, tertbutyl-sulfonylmethyl, 4-fluorobenzylsulfonylmethyl, 4-chlorophenyl-methylsulfonylmethyl, 2-thienyl, 3-(4-chlorophenylsulfonylmethyl)-2-thienyl, phenyl substituted with one or more substituents selected from

hydroxyl, chloro, fluoro, methoxy, -O- $CH_2$ -O-, amino, aminomethyl, methylsulfonyl, methyl, cyano, trifluoromethyl, and pyrrolyl,

unsubstituted pyridyl, and

4-pyridyl substituted with one or more substituents selected from chloro, fluoro, methyl, ethyl, - NH<sub>2</sub>, methoxy, ethoxy, -OH, -CO<sub>2</sub>H, phenoxyethylamino, methylamino, butylamino, isobutylamino, benzylamino, 4-fluorobenzylamino, 2-thienylethylamino, 3-pyridylmethylamino, 2-pyridylmethylamino, 2-furylmethylamino, 4-methoxybenzylamino, diethylamino, cyclopropylmethylamino, cyclopentylmethylamino, ethylaminoethylamino, diethylaminoethylamino, isopropylaminoethylamino, methylcarbonylaminoethylamino, methylcarbonylmethylamino, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl and azetidinyl; and

pharmaceutically acceptable salts thereof.

- 4. (Previously Presented) A Compound of Claim 1, and pharmaceutically acceptable salts thereof, wherein W is thiazol-4-yl.
  - 5. (Previously Presented) A Compound of Claim 1 wherein R<sup>1</sup> is selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>1</sub>-C<sub>4</sub>)alkyl-N(R<sup>5</sup>)<sub>2</sub>, -(C<sub>1</sub>-C<sub>4</sub>)alkyl-OR<sup>5</sup>, -(C<sub>3</sub>-C<sub>5</sub>)cycloalkyl, and -CF<sub>3</sub>;

- wherein R<sup>2</sup> is selected from H, halo, (C<sub>1</sub>-C<sub>3</sub>)alkyl, -NR<sup>5</sup><sub>2</sub>, -OR<sup>6</sup>, -(C<sub>1</sub>-C<sub>3</sub>)alkyl-OR<sup>5</sup>, -C(O)N(R<sup>5</sup>)<sub>2</sub>, -CO<sub>2</sub>R<sup>5</sup>, -(CH<sub>2</sub>)<sub>1-3</sub>-(5-6 membered saturated or partially unsaturated) heterocyclyl, -NHC(O)R<sup>5</sup>, and -C(O)R<sup>5</sup>;
- wherein R<sup>1</sup> and R<sup>2</sup> may be joined together with the pyridone ring to form optionally substituted 2-oxo-1,5,7,8-tetrahydro-2H-[1,6]naphthyridine, optionally substituted 5,6,7,8-tetrahydro-1H-[1,7]naphthyridin-2-one, optionally substituted 5,6,7,8-tetrahydro-1H-[1,7]naphthyridin-2-one, optionally substituted 5,6,7,8-tetrahydro-1H-quinolin-2-one, optionally substituted 7,8-dihydro-1H-quinolin-2-one, 7,8-dihydro-(1H,6H)-quinoline-2,5-dione or 1,5,7,8-tetrahydro-pyrano[4,3-b]pyridin-2-one;

wherein R<sup>3</sup> is H;

- wherein R<sup>5</sup> is independently selected from H, C<sub>1</sub>-C<sub>4</sub>-alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted heterocyclyl selected from piperazinyl, morpholinyl, pyrrolidinyl, and piperidinyl, optionally substituted pyridyl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, optionally substituted piperazinyl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, 4-morpholinyl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, pyrrolidinyl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, 1-piperidinyl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, -(C<sub>1</sub>-C<sub>3</sub>)-alkyl-N-((C<sub>1</sub>-C<sub>3</sub>)-alkyl)<sub>2</sub> and -(C<sub>1</sub>-C<sub>3</sub>)-alkyl-NH-(C<sub>1</sub>-C<sub>3</sub>)-alkyl; and pharmaceutically acceptable salts thereof.
- 6. (Previously Presented) A Compound of Claim 5 wherein R<sup>1</sup> is selected from methyl, ethyl, propyl, isopropyl, hydroxyethyl, dimethylaminomethyl, benzyloxymethyl, 4-methoxybenzyloxymethyl, methoxymethyl, cyclopropyl, and –CF<sub>3</sub>;
- wherein R<sup>2</sup> is selected from H, bromo, methyl, amino, isobutylamino, hydroxymethyl, aminocarbonyl, 4-methoxybenzylaminocarbonyl, 2-pyridylmethylaminocarbonyl, ethylaminocarbonyl, isopropylaminoethylaminocarbonyl, cyclopropylmethylaminocarbonyl, isobutylaminocarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, 4-morpholinylethoxycarbonyl, 1-pyrrolidinylethoxycarbonyl, 1-piperidinylethoxycarbonyl, diethylaminopropoxycarbonyl, carboxyl, 1,2,5,6-tetrahydro-1-pyridylmethyl, 1-piperidinylmethyl, 1-methyl-4-piperazinylmethyl, methylcarbonylamino, isobutylcarbonylamino, and 1-methyl-4-piperazinylcarbonyl;
- wherein R<sup>1</sup> and R<sup>2</sup> may be joined together with the pyridone ring to form 6-benzyloxycarbonyl-2-oxo-1,5,7,8-tetrahydro-2H-[1,6]naphthyridine, 5,6,7,8-tetrahydro-1H-[1,6]naphthyridin-2-

one, 7-Boc-5,6,7,8-tetrahydro-1H-[1,7]naphthyridin-2-one, 7-ethyl-5,6,7,8-tetrahydro-1H-[1,7]naphthyridin-2-one, 5-methyl-7,8-dihydro-1H-quinolin-2-one, 5-propylamino-5,6,7,8-tetrahydro-1H-quinolin-2-one, 5-propylimino-5,6,7,8-tetrahydro-1H-quinolin-2-one, 7,8-dihydro-(1H,6H)-quinoline-2,5-dione or 1,5,7,8-tetrahydro-pyrano[4,3-b]pyridin-2-one; and pharmaceutically acceptable salts thereof.

7. (Previously Presented) A Compound of Claim 4, and pharmaceutically acceptable salts thereof, wherein A is O; wherein Q is selected from N-methyl-N-(phenylsulfonyl)amino, 2-pyridylsulfonylmethyl, 2-thienylsulfonylmethyl, phenylsulfonylmethyl, (1-methyl)-1-(phenylsulfonyl)ethyl, 4-chlorophenyl-sulfonylmethyl, 2-furylmethylsulfonylmethyl, methylsulfonylmethyl, tert-butyl-sulfonylmethyl, 4-fluorobenzylsulfonylmethyl, 2-thienyl, phenyl substituted with one or more substituents selected from

chloro, fluoro, and -O-CH<sub>2</sub>-O-, unsubstituted pyridyl, and

, 1,

4-pyridyl substituted with one or more substituents selected from chloro, fluoro, -NH<sub>2</sub>, methoxy, ethoxy, phenoxyethylamino, methylamino, methyl, ethyl, butylamino, isobutylamino, benzylamino, 4-fluorobenzylamino, 2-thienylethylamino, 3-pyridylmethylamino, 2-pyridylmethylamino, 2-furylmethylamino, 4-methoxybenzylamino, diethylamino, cyclopropylmethylamino, cyclopentylmethylamino, ethylaminoethylamino, diethylaminoethylamino, isopropylaminoethylamino, methylcarbonylaminoethylamino, methylcarbonylmethylamino, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl and azetidinyl;

wherein R<sup>1</sup> is selected from methyl, ethyl, propyl, isopropyl, dimethylaminomethyl, hydroxyethyl, benzyloxymethyl, 4-methoxy-benzyloxymethyl, methoxymethyl, cyclopropyl, and -CF<sub>3</sub>;

wherein R<sup>2</sup> is selected from H, bromo, methyl, amino, isobutylamino, hydroxymethyl, aminocarbonyl, 4-methoxybenzylaminocarbonyl, 2-pyridylmethylaminocarbonyl, ethylaminocarbonyl, isopropylaminoethylaminocarbonyl, cyclopropylmethylaminocarbonyl, isobutylaminocarbonyl, ethoxycarbonyl, tertbutoxycarbonyl, 4-morpholinylethoxycarbonyl, 1-pyrrolidinylethoxycarbonyl, 1-piperidinylethoxycarbonyl, diethylaminopropoxycarbonyl, carboxyl, 1,2,5,6-tetrahydro-1-

pyridylmethyl, 1-piperidinylmethyl, 1-methyl-4-piperazinylmethyl, methylcarbonylamino, isobutylcarbonylamino, and 1-methyl-4-piperazinylcarbonyl;

wherein R<sup>1</sup> and R<sup>2</sup> may be joined together with the pyridone ring to form 6-benzyloxycarbonyl-2-oxo-1,5,7,8-tetrahydro-2H-[1,6]naphthyridine, 5,6,7,8-tetrahydro-1H-[1,6]naphthyridin-2-one, 7-Boc-5,6,7,8-tetrahydro-1H-[1,7]naphthyridin-2-one, 7-ethyl-5,6,7,8-tetrahydro-1H-[1,7]naphthyridin-2-one, 5-methyl-7,8-dihydro-1H-quinolin-2-one, 5-propylamino-5,6,7,8-tetrahydro-1H-quinolin-2-one, 7,8-dihydro-(1H,6H)-quinoline-2,5-dione or 1,5,7,8-tetrahydro-pyrano[4,3-b]pyridin-2-one; and wherein R<sup>3</sup> is H.

- 8. (Previously Presented) A Compound of Claim 1 wherein A is O; and pharmaceutically acceptable salts thereof.
  - 9. (Previously Presented) A compound of Claim 1 having Formula II

$$\mathbb{R}^7$$
 $\mathbb{R}^7$ 
 $\mathbb{R}^9$ 
 $\mathbb{R}^9$ 
 $\mathbb{R}^9$ 
 $\mathbb{R}^9$ 
 $\mathbb{R}^9$ 
 $\mathbb{R}^9$ 
 $\mathbb{R}^8$ 
 $\mathbb{R}^8$ 
 $\mathbb{R}^8$ 

wherein  $R^7$  is selected from -(C<sub>1</sub>-C<sub>3</sub>)alkyl, -(C<sub>1</sub>-C<sub>3</sub>)alkyl-N( $R^{10}$ )<sub>2</sub>, -(C<sub>1</sub>-C<sub>3</sub>)alkyl-OR<sup>10</sup>, -(C<sub>3</sub>-C<sub>5</sub>)cycloalkyl, and -CF<sub>3</sub>;

wherein  $R^8$  is selected from  $R^{10}SO_2$ -( $C_1$ - $C_6$ )alkyl-,  $R^{11}SO_2NH$ - and substituted or unsubstituted 5-6 membered heteroaryl;

wherein  $R^9$  is selected from H, halo,  $(C_1-C_3)$ alkyl,  $-NR^{10}_2$ ,  $-(C_1-C_3)$ alkyl $-OR^{10}$ ,  $-C(O)N(R^{10})_2$ ,  $-CO_2R^{10}$ ,  $(CH_2)_{1-3}$ -(5-6 membered saturated or partially unsaturated heterocyclyl,  $-CO_2R^{10}$ ),  $(CH_2)_{1-3}$ -(5-6 membered saturated or partially unsaturated heterocyclyl,  $-CO_2R^{10}$ ),  $(CH_2)_{1-3}$ -(5-6 membered saturated or partially unsaturated heterocyclyl,  $-CO_2R^{10}$ ),  $(CH_2)_{1-3}$ -(5-6 membered saturated or partially unsaturated heterocyclyl,  $-CO_2R^{10}$ ),  $-CO_2R^{10}$ 

NHC(O) $R^{10}$ , and -C(O) $R^{10}$ ;

- wherein R<sup>10</sup> is independently selected from H, (C<sub>1</sub>-C<sub>4</sub>)alkyl, optionally substituted phenyl, optionally substituted phenyl-(C<sub>1</sub>-C<sub>2</sub>)alkyl, optionally substituted furyl-(C<sub>1</sub>-C<sub>2</sub>)-alkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl-(C<sub>1</sub>-C<sub>2</sub>)-alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkylamino-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, phenyloxy-(C<sub>1</sub>-C<sub>3</sub>)alkyl-, (C<sub>1</sub>-C<sub>2</sub>)alkylcarbonyl-(C<sub>1</sub>-C<sub>2</sub>)alkyl- and optionally substituted heterocyclyl selected from pyridyl and thienyl; and
- wherein R<sup>11</sup> is independently selected from (C<sub>1</sub>-C<sub>4</sub>)alkyl, optionally substituted phenyl, optionally substituted phenyl-(C<sub>1</sub>-C<sub>2</sub>)alkyl, optionally substituted furyl-(C<sub>1</sub>-C<sub>2</sub>)-alkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl-(C<sub>1</sub>-C<sub>2</sub>)-alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkylamino-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, phenyloxy-(C<sub>1</sub>-C<sub>3</sub>)alkyl-, (C<sub>1</sub>-C<sub>2</sub>)alkylcarbonyl-(C<sub>1</sub>-C<sub>2</sub>)alkyl, and optionally substituted heterocyclyl selected from pyridyl and thienyl;

and pharmaceutically acceptable salts thereof; provided R<sup>7</sup> is not CF<sub>3</sub> when R<sup>9</sup> is ethoxycarbonyl and when R<sup>8</sup> is 4-pyridyl or 2-chloro-4-pyridyl.

10. (Previously Presented) A Compound of Claim 9 wherein R<sup>7</sup> is selected from methyl, ethyl, propyl, isopropyl, dimethylaminomethyl, benzyloxymethyl, hydroxyethyl, 4-methoxybenzyloxymethyl, methoxymethyl, cyclopropyl, and –CF<sub>3</sub>; wherein R<sup>8</sup> is selected from N-methyl-N-(phenylsulfonyl)amino, 2-pyridylsulfonylmethyl, 2-thienylsulfonylmethyl, phenylsulfonylmethyl, (1-methyl)-1-(phenylsulfonyl)ethyl, 4-chlorophenyl-sulfonylmethyl, 2-furylmethylsulfonylmethyl, methylsulfonylmethyl, tert-butyl-sulfonylmethyl, 4-fluorobenzylsulfonylmethyl, 2-thienyl, phenyl substituted with one or more substituents selected from

chloro, fluoro, and -O-CH<sub>2</sub>-O-, unsubstituted pyridyl, and

4-pyridyl substituted with one or more substituents selected from chloro, fluoro, -NH<sub>2</sub>, methoxy, ethoxy, phenoxyethylamino, methylamino, methyl, ethyl, butylamino, isobutylamino, benzylamino, 4-fluorobenzylamino, 2-thienylethylamino, 3-pyridylmethylamino, 2-pyridylmethylamino, 2-furylmethylamino, 4-methoxybenzylamino, diethylamino, cyclopentylmethylamino, ethylaminoethylamino, diethylamino, diethylamino, diethylamino, methylamino, methylamino, methylamino,

methylcarbonylmethylamino, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl and azetidinyl; and

wherein R<sup>9</sup> is selected from H, bromo, methyl, amino, isobutylamino, hydroxymethyl, aminocarbonyl, 4-methoxybenzylaminocarbonyl, 2-pyridylmethylaminocarbonyl, ethylaminocarbonyl, isopropylaminoethylaminocarbonyl, cyclopropylmethylaminocarbonyl, isobutylaminocarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, 4-morpholinylethoxycarbonyl, 1-pyrrolidinylethoxycarbonyl, 1-piperidinylethoxycarbonyl, diethylaminopropoxycarbonyl, carboxyl, 1,2,5,6-tetrahydro-1-pyridylmethyl, 1-piperidinylmethyl, 1-methyl-4-piperazinylmethyl, methylcarbonylamino, isobutylcarbonylamino, and 1-methyl-4-piperazinylcarbonyl; and pharmaceutically acceptable salts thereof.

### 11. (Previously Presented) A compound of Claim 1 having Formula III

wherein  $R^8$  is selected from  $R^{11}SO_2$ -( $C_1$ - $C_6$ )alkyl-,  $R^{11}SO_2NH$ and substituted or unsubstituted 5-6 membered heteroaryl;

wherein ring A together with the pyridone ring forms optionally substituted 2-oxo-1,5,7,8-tetrahydro-2H-[1,6]naphthyridine, optionally substituted 5,6,7,8-tetrahydro-1H-[1,6]naphthyridin-2-one, optionally substituted 5,6,7,8-tetrahydro-1H-quinolin-2-one, optionally substituted 5,6,7,8-tetrahydro-1H-[1,7]naphthyridin-2-one, or 1,5,7,8-tetrahydro-pyrano[4,3-b]pyridin-2-one; and

wherein  $R^{11}$  is independently selected from  $(C_1-C_4)$ alkyl, optionally substituted phenyl, optionally substituted phenyl- $(C_1-C_2)$ alkyl, optionally substituted furyl- $(C_1-C_2)$ -alkyl,

optionally substituted  $C_3$ - $C_6$  cycloalkyl- $(C_1$ - $C_2)$ -alkyl,  $(C_1$ - $C_3)$ alkylamino- $(C_1$ - $C_3)$ -alkyl, phenyloxy- $(C_1$ - $C_3)$ alkyl,  $(C_1$ - $C_2)$ alkylcarbonyl- $(C_1$ - $C_2)$ alkyl, and optionally substituted heterocyclyl selected from pyridyl and thienyl;

and pharmaceutically acceptable salts thereof.

12. (Previously Presented) A Compound of Claim 11 wherein R<sup>8</sup> is selected from N-methyl-N-(phenylsulfonyl)amino, 2-pyridylsulfonylmethyl, 2-thienylsulfonylmethyl, phenylsulfonylmethyl, (1-methyl)-1-(phenylsulfonyl)ethyl, 4-chlorophenyl-sulfonylmethyl, 2-furylmethylsulfonylmethyl, methylsulfonylmethyl, tert-butyl-sulfonylmethyl, 4-fluorobenzylsulfonylmethyl, 2-thienyl, phenyl substituted with one or more substituents selected from chloro, fluoro, and -O-CH<sub>2</sub>-O-,

unsubstituted pyridyl, and

٠١.

4

4-pyridyl substituted with one or more substituents selected from chloro, fluoro, -NH<sub>2</sub>, methoxy, ethoxy, phenoxyethylamino, methylamino, methyl, ethyl, butylamino, isobutylamino, benzylamino, 4-fluorobenzylamino, 2-thienylethylamino, 3-pyridylmethylamino, 2-pyridylmethylamino, 2-furylmethylamino, 4-methoxybenzylamino, diethylamino, cyclopropylmethylamino, cyclopentylmethylamino, ethylaminoethylamino, diethylamino, isopropylaminoethylamino, methylcarbonylaminoethylamino, methylcarbonylmethylamino, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl and azetidinyl;

and pharmaceutically acceptable salts thereof.

13. (Previously Presented) A Compound of Claim 12 and pharmaceutically acceptable salts thereof selected from:

Phenylmethyl 2-oxo-3-(2-(4-pyridyl)(1,3-thiazol-4-yl))-1,5,6,7,8-pentahydropyridino[3,2-c]pyridine-6-carboxylate;

3-(2-(4-Pyridyl)-1,3-thiazol-4-yl)-1,7,8-trihydro-5H-pyrano[4,3-b]pyridin-2-one;

7-Ethyl-3-(2-(4-pyridyl)(1,3-thiazol-4-yl))-1,5,6,7,8-pentahydropyridino[3,2-c]pyridin-2-one;

tert-Butyl 2-oxo-3-(2-(4-pyridyl)(1,3-thiazol-4-yl))-1,5,6,7,8-pentahydropyridino[3,2-c]pyridine-6-carboxylate;

3-(2-(4-Pyridyl)-1,3-thiazol-4-yl)-1,5,6,7,8-pentahydropyridino[3,2-c]pyridin-2-one, dihydrochloride; and

6-Methyl-3-(2-pyridin-4-yl-thiazol-4-yl)-5,6,7,8-tetrahydro-1H-[1,6]naphthyridin-2-one.

## 14. (Previously Presented) A compound of Formula I'

$$\begin{array}{c|c}
R^1 & H \\
\hline
 & 1 \\
\hline
 & 2 \\
\hline
 & 5 \\
\hline
 & 4 \\
\hline
 & 3 \\
\hline
 & Q \\
\hline
 & I'
\end{array}$$

wherein A is O or S;


填

wherein Q is selected from -N(R<sup>5</sup>)<sub>2</sub>, -NR<sup>5</sup>C(O)R<sup>5</sup>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-OR<sup>5</sup>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-S(O)<sub>n</sub>R<sup>6</sup>,

SO<sub>2</sub>R<sup>6</sup>, substituted aryl, an unsubstituted or substituted monocyclic or bicyclic, non-aromatic carbocyclic ring, an unsubstituted or substituted monocyclic or bicyclic, heteroaryl ring, and an unsubstituted or substituted monocyclic or bicyclic, non-aromatic heterocyclic ring,

wherein a ring is unsubstituted or substituted with one or more groups selected from halo, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>2</sub>-C<sub>8</sub>)alkynyl, (C<sub>2</sub>-C<sub>8</sub>)alkenyl, -OR<sup>5</sup>, -O-(CH<sub>2</sub>)<sub>1-2</sub>-O-, -N(R<sup>5</sup>)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-N(R<sup>5</sup>)<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)haloalkyl, lower cyanoalkyl, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-OR<sup>5</sup>, lower alkylaminoalkoxy, lower aminoalkoxyalkyl, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-S(O)<sub>n</sub>R<sup>5</sup>, -N(R<sup>5</sup>)-(C<sub>1</sub>-C<sub>8</sub>)alkyl-N(R<sup>5</sup>)<sub>2</sub>, -N(R<sup>5</sup>)-(C<sub>1</sub>-C<sub>8</sub>)alkyl-OR<sup>5</sup>, -N(R<sup>5</sup>)-(C<sub>1</sub>-C<sub>8</sub>)alkyl-NHC(O)R<sup>5</sup>, -N(R<sup>5</sup>)-(C<sub>1</sub>-C<sub>8</sub>)alkyl-C(O)N(R<sup>5</sup>)<sub>2</sub>, lower alkoxyalkyl, -S(O)<sub>n</sub>R<sup>5</sup>, -SO<sub>2</sub>NR<sup>5</sup>R<sup>5</sup>, -NR<sup>5</sup>S(O)<sub>n</sub>R<sup>5</sup>, cyano, nitro, optionally substituted (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, optionally substituted aryl, optionally substituted 4-7 membered heterocyclyl, optionally substituted phenoxyalkyl, optionally substituted heterocyclyloxyalkyl, -C(O)N(R<sup>5</sup>)<sub>2</sub>, -CO<sub>2</sub>R<sup>5</sup>, -CO<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, -SO<sub>2</sub>NHC(O)R<sup>5</sup>, optionally substituted phenylalkyl, optionally substituted heterocyclylalkyl, -NR<sup>5</sup>C(O)N(R<sup>5</sup>)<sub>2</sub>, -NR<sup>5</sup>CO<sub>2</sub>R<sup>5</sup> and -C(O)R<sup>5</sup>;

#### wherein W is selected from



wherein n is 0, 1 or 2;

wherein R<sup>1</sup> is selected from H, -OR<sup>6</sup>, halo, aryl, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>2</sub>-C<sub>8</sub>)alkenyl, (C<sub>2</sub>-C<sub>8</sub>)alkynyl, (C<sub>1</sub>-C<sub>8</sub>)perfluoroalkyl, -NR<sup>5</sup><sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-NR<sup>5</sup><sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-OR<sup>5</sup>, -S(O)<sub>n</sub>-alkyl, -S(O)<sub>n</sub>-aryl, -S(O)<sub>n</sub>-heteroaryl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, nitro, heterocyclyl, -NR<sup>5</sup>SO<sub>2</sub>R<sup>5</sup>, -C(O)N(R<sup>5</sup>)<sub>2</sub>, -CO<sub>2</sub>R<sup>5</sup>, -(CR<sup>5</sup><sub>2</sub>)<sub>1-8</sub>aryl, -(CR<sup>5</sup><sub>2</sub>)<sub>1-8</sub>heterocyclyl, -NR<sup>5</sup>C(O)N(R<sup>5</sup>)<sub>2</sub>, -NR<sup>5</sup>C(O)R<sup>5</sup>, -NR<sup>5</sup>CO<sub>2</sub>R<sup>5</sup>, and -C(O)R<sup>5</sup>; wherein R<sup>1</sup> and R<sup>2</sup> may be joined to form a 5-10 membered saturated or partially unsaturated carbocyclic or heterocyclic ring;

wherein  $R^2$  is selected from H,  $-OR^6$ , halo, aryl,  $(C_1-C_8)$ alkyl,  $(C_2-C_8)$ alkenyl,  $(C_2-C_8)$ alkynyl,  $(C_1-C_8)$ perfluoroalkyl,  $-NR^5_2$ ,  $-(C_1-C_8)$ alkyl $-NR^5_2$ ,  $-(C_1-C_8)$ alkyl $-OR^5$ ,  $-S(O)_n$ -alkyl,  $-S(O)_n$ -aryl,  $-S(O)_n$ -heteroaryl,  $(C_3-C_{10})$ cycloalkyl, nitro, heterocyclyl,  $-NR^5SO_2R^5$ ,  $-C(O)N(R^5)_2$ ,  $-CO_2R^5$ ,  $-(CR^5_2)_{1-8}$ aryl,  $-(CR^5_2)_{1-8}$ heterocyclyl,  $-NR^5C(O)N(R^5)_2$ ,  $-NR^5C(O)R^5$ ,  $-NR^5CO_2R^5$ , and  $-C(O)R^5$ ;

wherein R³ is selected from H, -OR6, halo, aryl, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>2</sub>-C<sub>8</sub>)alkenyl, (C<sub>2</sub>-C<sub>8</sub>)alkynyl, (C<sub>1</sub>-C<sub>8</sub>)perfluoroalkyl, -NR<sup>5</sup><sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-NR<sup>5</sup><sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)alkyl-OR<sup>5</sup>, -S(O)<sub>n</sub>-alkyl, -S(O)<sub>n</sub>-aryl, -S(O)<sub>n</sub>-heteroaryl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, nitro, heterocyclyl, -NR<sup>5</sup>SO<sub>2</sub>R<sup>5</sup>, -C(O)N(R<sup>5</sup>)<sub>2</sub>, -CO<sub>2</sub>R<sup>5</sup>, -(CR<sup>5</sup><sub>2</sub>)<sub>1-8</sub>aryl, -(CR<sup>5</sup><sub>2</sub>)<sub>1-8</sub>heterocyclyl, -NR<sup>5</sup>C(O)N(R<sup>5</sup>)<sub>2</sub>, -NR<sup>5</sup>C(O)R<sup>5</sup>, -NR<sup>5</sup>CO<sub>2</sub>R<sup>5</sup>, and -C(O)R<sup>5</sup>; wherein R² and R³ may be joined to form a 5-10 membered saturated or partially unsaturated carbocyclic or heterocyclic ring;

wherein R<sup>4</sup> is independently selected from H, and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

wherein R<sup>5</sup> is independently selected from H, lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl-alkyl, lower aminoalkyl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkylamino-(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylamino-(C<sub>1</sub>-C<sub>6</sub>)alkyl, aryloxyalkyl, alkylcarbonylalkyl, and lower perfluoroalkyl; and

wherein R<sup>6</sup> is independently selected from lower alkyl, optionally substituted aryl, optionally substituted aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl-(C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl-(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylamino-(C<sub>1</sub>-C<sub>6</sub>)alkyl, aryloxy-(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, and lower perfluoroalkyl;

wherein each aryl, heteroaryl, cycloalkyl, and heterocyclyl moiety of any R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, and Q is optionally substituted with one or more groups selected from halo, -NH<sub>2</sub>, -OH, oxo, - CO<sub>2</sub>H, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxyalkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, phenyl, and heterocyclyl;

and pharmaceutically acceptable salts thereof;

provided R<sup>1</sup> is not CF<sub>3</sub> when R<sup>2</sup> is ethoxycarbonyl, when R<sup>3</sup> is H, when W is thiazol-4-yl and when Q is 4-pyridyl or 2-chloro-4-pyridyl; further provided Q is not 4-pyridyl, when W is thiazol-2-yl, when R<sup>1</sup>, R<sup>3</sup>, and R<sup>2</sup> are H; further provided Q is not 2-nitro-5-furyl when W is thiazol-2-yl, when R<sup>1</sup> is methyl, when R<sup>3</sup> is H, and when R<sup>2</sup> is H; further provided Q is not phenyl when W is thiazol-2-yl, when R<sup>1</sup> is methyl, when R<sup>3</sup> is methyl, and when R<sup>2</sup> is H; further provided Q is not phenyl, 3,4-diacetylphenyl or 3,4-dihydroxyphenyl, when W is thiazol-2-yl, when R<sup>1</sup> is H, when R<sup>3</sup> is H, and when R<sup>2</sup> is H; and further provided Q is not 3-cyano-6-methyl-2-oxo-1,2-dihydro-5-pyridyl, when W is thiazol-2-yl, when R<sup>1</sup> is methyl, when R<sup>3</sup> is H, and when R<sup>2</sup> is acetyl.

15. (Previously Presented) A Compound of Claim 14 wherein Q is selected from

 $R^6SO_2$ -( $C_1$ - $C_6$ )alkyl-,  $R^4$  , substituted phenyl, and substituted or unsubstituted 5-6 membered heteroaryl;

wherein  $R^4$  is independently selected from H, and  $(C_1\text{-}C_2)$ alkyl; and

wherein  $R^6$  is independently selected from  $(C_1-C_4)$ alkyl, optionally substituted phenyl, optionally substituted phenyl- $(C_1-C_2)$ alkyl, optionally substituted furyl- $(C_1-C_2)$ -alkyl, optionally substituted  $C_3-C_6$  cycloalkyl- $(C_1-C_2)$ -alkyl,  $(C_1-C_3)$ alkylamino- $(C_1-C_3)$ -alkyl-, phenyloxy- $(C_1-C_3)$ alkyl-,  $(C_1-C_2)$ alkylcarbonyl- $(C_1-C_2)$ alkyl- and optionally substituted heterocyclyl selected from pyridyl and thienyl; and pharmaceutically acceptable salts thereof.

16. (Previously Presented) A Compound of Claim 15 wherein Q is selected from phenylsulfonylamino, N-methyl-N-(2-pyridylsulfonyl)amino, N-methyl-N-(3-pyridylsulfonyl)amino, N-methyl-N-(4-pyridylsulfonyl)amino, N-methyl-N-(2-thienylsulfonyl)amino, N-methyl-N-(phenylsulfonyl)amino, 2-pyridylsulfonylmethyl, 3-pyridylsulfonylmethyl, 4-pyridylsulfonylmethyl, 2-thienylsulfonylmethyl, 3-thienylsulfonylmethyl, phenylsulfonylmethyl, (1-methyl)-1-(phenylsulfonyl)ethyl, 4-chlorophenyl-sulfonylmethyl, tert-butyl-sulfonylmethyl, 3-trifluoromethylbenzyl-sulfonylmethyl, methylsulfonylmethyl, tert-butyl-sulfonylmethyl, 4-fluorobenzylsulfonylmethyl, 4-chlorophenyl-methylsulfonylmethyl, 2-thienyl, 3-(4-chlorophenylsulfonylmethyl)-2-thienyl, phenyl substituted with one or more substituents selected from

hydroxyl, chloro, fluoro, methoxy, -O-CH<sub>2</sub>-O-, amino, aminomethyl, methylsulfonyl, methyl, cyano, trifluoromethyl, and pyrrolyl,

unsubstituted pyridyl, and

, t,

4

4-pyridyl substituted with one or more substituents selected from chloro, fluoro, methyl, ethyl, - NH<sub>2</sub>, methoxy, ethoxy, -OH, -CO<sub>2</sub>H, phenoxyethylamino, methylamino, dimethylamino, butylamino, isobutylamino, benzylamino, 4-fluorobenzylamino, 2-thienylethylamino, 3-pyridylmethylamino, 2-pyridylmethylamino, 2-furylmethylamino, 4-methoxybenzylamino, diethylamino, cyclopropylmethylamino, cyclopentylmethylamino, ethylaminoethylamino, diethylaminoethylamino, isopropylaminoethylamino, methylcarbonylaminoethylamino, methylcarbonylmethylamino, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl and azetidinyl; and

pharmaceutically acceptable salts thereof.

- 17. (Previously Presented) A Compound of Claim 14, and pharmaceutically acceptable salts thereof, wherein W is thiazol-4-yl.
- 18. (Previously Presented) A Compound of Claim 14 wherein  $R^1$  is selected from  $(C_1-C_6)$  alkyl,  $-(C_1-C_4)$  alkyl- $N(R^5)_2$ ,  $-(C_1-C_4)$  alkyl- $OR^5$ ,  $(C_3-C_5)$  cycloalkyl and  $-CF_3$ ; wherein  $R^5$  is independently selected from H,  $C_1-C_5$ -alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted pyridyl- $(C_1-C_3)$ -alkyl,

optionally substituted piperazinyl- $(C_1-C_3)$ -alkyl, 4-morpholinyl- $(C_1-C_3)$ -alkyl, optionally substituted piperidinyl- $(C_1-C_3)$ -alkyl, optionally substituted piperidinyl- $(C_1-C_3)$ -alkyl, optionally substituted  $C_3-C_6$  cycloalkyl- $(C_1-C_3)$ -alkyl, amino- $(C_1-C_4)$ -alkyl-, benzylamino- $(C_1-C_3)$ -alkyl-,  $[N-(C_1-C_3)$ -alkyl-N-benzylamino]- $(C_1-C_3)$ -alkyl-,  $-(C_1-C_3)$ -alkyl-N- $-(C_1-C_3)$ -alkyl-N- $-(C_1-C_3)$ -alkyl-NH- $-(C_1-C_3)$ -alkyl and optionally substituted heterocyclyl selected from piperazinyl, morpholinyl, pyrrolidinyl and piperidinyl; and pharmaceutically acceptable salts thereof.

٠٠,

- 19. (Previously Presented) A Compound of Claim 18 wherein R<sup>1</sup> is selected from methyl, ethyl, propyl, isopropyl, dimethylaminomethyl, 1-pyrrolidinyltheyl, benzyloxymethyl, benzyloxymethyl, denzyloxymethyl, denzyloxymethyl, nethoxymethyl, cyclopropyl and · CF<sub>3</sub>; and pharmaceutically acceptable salts thereof.
- 20. (Previously Presented) A Compound of Claim 14 wherein  $R^2$  is selected from H, halo,  $(C_1-C_3)$ alkyl,  $-NR^5_2$ ,  $-OR^6$ ,  $-(C_1-C_3)$ alkyl- $OR^5$ ,  $-(C_1-C_3)$ alkyl- $NR^5_2$ ,  $-C(O)N(R^5)_2$ ,  $-CO_2R^5$ ,  $-(CH_2)_{1-3}$ -(5-6 membered saturated or partially unsaturated) heterocyclyl, 5-6 membered saturated or partially unsaturated heterocyclyl,  $-NHC(O)R^5$ , and  $-C(O)R^5$ ; wherein  $R^5$  is independently selected from H,  $C_1$ - $C_5$ -alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted pyridyl- $(C_1$ - $C_3$ )-alkyl, optionally substituted piperazinyl- $(C_1$ - $C_3$ )-alkyl, 4-morpholinyl- $(C_1$ - $C_3$ )-alkyl, optionally substituted pyrrolidinyl- $(C_1$ - $C_3$ )-alkyl, optionally substituted piperidinyl- $(C_1$ - $C_3$ )-alkyl, optionally substituted  $C_3$ - $C_6$  cycloalkyl- $C_1$ - $C_3$ -alkyl, amino- $C_1$ - $C_4$ -alkyl-, benzylamino- $C_1$ - $C_3$ -alkyl-,  $C_1$ - $C_3$ -alkyl-N-benzylamino]- $C_1$ - $C_3$ -alkyl-N- $C_1$ - $C_3$ -alkyl-N- $C_1$ - $C_3$ -alkyl-NH- $C_1$ - $C_3$ -alkyl and optionally substituted heterocyclyl selected from piperazinyl, morpholinyl, pyrrolidinyl and piperidinyl; and pharmaceutically acceptable salts thereof.
- 21. (Previously Presented) A Compound of Claim 20 wherein R<sup>2</sup> is selected from H, bromo, methyl, hydroxymethyl, 1,2,5,6-tetrahydro-1-pyridylmethyl, 1-piperidinylmethyl, 1-methyl-4-piperazinylmethyl, (N-diethylaminoethyl-N-methyl)aminomethyl, (N-dimethylaminoethyl-N-ethyl)aminomethyl, 4,5-dihydro-oxazol-2-yl, 5-methyl-4,5-dihydro-

oxazol-2-yl, 2-furyl, amino, isobutylamino, 3-methylbutylamino, ethylcarbonyl, aminocarbonyl, 4-methoxybenzylaminocarbonyl, 2-pyridylmethylaminocarbonyl, 4pyridylmethylaminocarbonyl, dimethylaminocarbonyl, ethylaminocarbonyl, isopropylaminoethylaminocarbonyl, cyclopropylmethylaminocarbonyl, isobutylaminocarbonyl, ethoxycarbonyl, propoxycarbonyl, 1-methylpropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, 2-thienylethoxycarbonyl, 4-morpholinylethoxycarbonyl, (4-piperidinyl)methoxycarbonyl, (1-piperazinyl)ethoxycarbonyl, (1-methyl-piperidin-3yl)oxycarbonyl, (1-methyl-piperidin-4-yl)oxycarbonyl, (1-ethyl-piperidin-3-yl)oxycarbonyl, (1methyl-pyrrolidin-3-yl)oxycarbonyl, 1-pyrrolidinylethoxycarbonyl, 2-oxo-pyrrolidin-1ylethoxycarbonyl, 2-oxo-pyrrolidin-1-ylpropoxycarbonyl, 1-methyl-2pyrrolidinylethoxycarbonyl, 1-piperidinylethoxycarbonyl, diethylaminoethoxycarbonyl, diisopropylaminoethoxycarbonyl, (N-ethyl-N-benzylamino)ethoxycarbonyl, diethylaminopropoxycarbonyl, dimethylaminoethoxycarbonyl, 2-(dimethylamino)-1-(methyl)ethoxycarbonyl, 2-(diethylamino)-1-(methyl)ethoxycarbonyl, carboxyl, methylcarbonylamino, isobutylcarbonylamino, methylaminomethylcarbonylamino, dimethylaminomethylcarbonylamino, tert-butylaminomethylcarbonylamino, (1-amino-2methylpropyl)carbonylamino, 1-piperidinylmethylcarbonylamino, 1piperidinylethýlcarbonylamino, 1-piperidinylpropylcarbonylamino, aminomethylcarbonylamino and 1-methyl-4-piperazinylcarbonyl; and pharmaceutically acceptable salts thereof.

. 1,

٠,

- 22. (Previously Presented) A Compound of Claim 14 wherein R<sup>1</sup> and R<sup>2</sup> may be joined together with the pyridone ring to form optionally substituted 2-oxo-1,5,7,8-tetrahydro-2H-[1,6]naphthyridine, optionally substituted 5,6,7,8-tetrahydro-1H-[1,6]naphthyridin-2-one, optionally substituted 5,6,7,8-tetrahydro-1H-[1,7]naphthyridin-2-one, optionally substituted 5,6,7,8-tetrahydro-1H-quinolin-2-one, optionally substituted 7,8-dihydro-1H-quinolin-2-one, 7,8-dihydro-(1H,6H)-quinoline-2,5-dione or 1,5,7,8-tetrahydro-pyrano[4,3-b]pyridin-2-one; and pharmaceutically acceptable salts thereof.
- 23. (Previously Presented) A Compound of Claim 22, wherein R<sup>1</sup> and R<sup>2</sup> are joined together with the pyridone ring to form 6-benzyloxycarbonyl-2-oxo-1,5,7,8-tetrahydro-2H-[1,6]naphthyridine, 5,6,7,8-tetrahydro-1H-[1,6]naphthyridin-2-one, 7-Boc-5,6,7,8-tetrahydro-

1H-[1,7]naphthyridin-2-one, 7-ethyl-5,6,7,8-tetrahydro-1H-[1,7]naphthyridin-2-one, 5-methyl-7,8-dihydro-1H-quinolin-2-one, 5-propylamino-5,6,7,8-tetrahydro-1H-quinolin-2-one, 5-propylimino-5,6,7,8-tetrahydro-1H-quinolin-2-one, 7,8-dihydro-(1H,6H)-quinoline-2,5-dione or 1,5,7,8-tetrahydro-pyrano[4,3-b]pyridin-2-one; and pharmaceutically acceptable salts thereof.

- 24. (Previously Presented) A Compound of Claim 14 wherein R<sup>3</sup> is H; and pharmaceutically acceptable salts thereof.
- 25. (Previously Presented) A Compound of Claim 14 wherein A is O; and pharmaceutically acceptable salts thereof.
- 26. (Previously Presented) A Compound of Claim 14, and pharmaceutically acceptable salts thereof, wherein A is O; wherein Q is selected from N-methyl-N-(phenylsulfonyl)amino, 2-pyridylsulfonylmethyl, 2-thienylsulfonylmethyl, phenylsulfonylmethyl, (1-methyl)-1-(phenylsulfonyl)ethyl, 4-chlorophenyl-sulfonylmethyl, 2-furylmethylsulfonylmethyl, methylsulfonylmethyl, tert-butyl-sulfonylmethyl, 4-fluorobenzylsulfonylmethyl, 2-thienyl, phenyl substituted with one or more substituents selected from

chloro, fluoro, and -O-CH<sub>2</sub>-O-, unsubstituted pyridyl, and

٠٦

4-pyridyl substituted with one or more substituents selected from chloro, fluoro, -NH<sub>2</sub>, methoxy, ethoxy, methyl, ethyl, phenoxyethylamino, methylamino, dimethylamino, butylamino, isobutylamino, benzylamino, 4-fluorobenzylamino, 2-thienylethylamino, 3-pyridylmethylamino, 2-pyridylmethylamino, 2-furylmethylamino, 4-methoxybenzylamino, diethylamino, cyclopropylmethylamino, cyclopentylmethylamino, ethylaminoethylamino, diethylaminoethylamino, isopropylaminoethylamino, methylcarbonylaminoethylamino, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl and azetidinyl;

wherein R<sup>1</sup> is selected from methyl, ethyl, propyl, isopropyl, dimethylaminomethyl, hydroxyethyl, benzyloxymethyl, 4-methoxy-benzyloxymethyl, methoxymethyl, cyclopropyl, and -CF<sub>3</sub>;

wherein R<sup>2</sup> is selected from H. bromo, methyl, amino, isobutylamino, hydroxymethyl,

aminocarbonyl, 4-methoxybenzylaminocarbonyl, 2-pyridylmethylaminocarbonyl, ethylaminocarbonyl, isopropylaminoethylaminocarbonyl, cyclopropylmethylaminocarbonyl, isobutylaminocarbonyl, ethoxycarbonyl, tertbutoxycarbonyl, 4-morpholinylethoxycarbonyl, 1-pyrrolidinylethoxycarbonyl, 1-piperidinylethoxycarbonyl, diethylaminopropoxycarbonyl, carboxyl, 1,2,5,6-tetrahydro-1-pyridylmethyl, 1-piperidinylmethyl, 1-methyl-4-piperazinylmethyl, methylcarbonylamino, isobutylcarbonylamino, and 1-methyl-4-piperazinylcarbonyl;

٠),

wherein R<sup>1</sup> and R<sup>2</sup> may be joined together with the pyridone ring to form 6-benzyloxycarbonyl-2-oxo-1,5,7,8-tetrahydro-2H-[1,6]naphthyridine, 5,6,7,8-tetrahydro-1H-[1,6]naphthyridin-2-one, 7-Boc-5,6,7,8-tetrahydro-1H-[1,7]naphthyridin-2-one, 7-ethyl-5,6,7,8-tetrahydro-1H-[1,7]naphthyridin-2-one, 5-methyl-7,8-dihydro-1H-quinolin-2-one, 5-propylamino-5,6,7,8-tetrahydro-1H-quinolin-2-one, 7,8-dihydro-1H-quinolin-2-one, 5-propylimino-5,6,7,8-tetrahydro-1H-quinolin-2-one, 7,8-dihydro-(1H,6H)-quinoline-2,5-dione or 1,5,7,8-tetrahydro-pyrano[4,3-b]pyridin-2-one; and wherein R<sup>3</sup> is H.

# 27. (Previously Presented) A compound of Claim 14 having Formula II'

$$\mathbb{R}^7$$
 $\mathbb{R}^9$ 
 $\mathbb{R}^9$ 
 $\mathbb{R}^9$ 
 $\mathbb{R}^9$ 
 $\mathbb{R}^9$ 
 $\mathbb{R}^9$ 
 $\mathbb{R}^8$ 
 $\mathbb{R}^8$ 
 $\mathbb{R}^8$ 

wherein  $R^7$  is selected from -(C<sub>1</sub>-C<sub>3</sub>)alkyl, -(C<sub>1</sub>-C<sub>3</sub>)alkyl-N( $R^{10}$ )<sub>2</sub>, -(C<sub>1</sub>-C<sub>3</sub>)alkyl-OR<sup>10</sup>, -(C<sub>3</sub>-C<sub>5</sub>)cycloalkyl, and -CF<sub>3</sub>;

wherein  $R^8$  is selected from  $R^{10}SO_2$ -( $C_1$ - $C_6$ )alkyl-,  $R^{11}SO_2NH$ and substituted or unsubstituted 5-6 membered heteroaryl;

- wherein R<sup>9</sup> is selected from H, halo, (C<sub>1</sub>-C<sub>3</sub>)alkyl, -NR<sup>10</sup><sub>2</sub>, -(C<sub>1</sub>-C<sub>3</sub>)alkyl-OR<sup>10</sup>, -C(O)N(R<sup>10</sup>)<sub>2</sub>, -CO<sub>2</sub>R<sup>10</sup>, (CH<sub>2</sub>)<sub>1-3</sub>-(5-6 membered saturated or partially unsaturated heterocyclyl, -NHC(O)R<sup>10</sup>, and -C(O)R<sup>10</sup>;
- wherein  $R^{10}$  is independently selected from H,  $(C_1-C_4)$ alkyl, optionally substituted phenyl, optionally substituted phenyl- $(C_1-C_2)$ alkyl, optionally substituted furyl- $(C_1-C_2)$ -alkyl, optionally substituted  $C_3-C_6$  cycloalkyl- $(C_1-C_2)$ -alkyl,  $(C_1-C_3)$ alkylamino- $(C_1-C_3)$ -alkyl-, phenyloxy- $(C_1-C_3)$ alkyl-,  $(C_1-C_2)$ alkylcarbonyl- $(C_1-C_2)$ alkyl- and optionally substituted heterocyclyl selected from pyridyl and thienyl; and
- wherein  $R^{11}$  is independently selected from  $(C_1-C_4)$ alkyl, optionally substituted phenyl, optionally substituted phenyl- $(C_1-C_2)$ alkyl, optionally substituted furyl- $(C_1-C_2)$ -alkyl, optionally substituted  $C_3-C_6$  cycloalkyl- $(C_1-C_2)$ -alkyl,  $(C_1-C_3)$ alkylamino- $(C_1-C_3)$ -alkyl-, phenyloxy- $(C_1-C_3)$ alkyl-,  $(C_1-C_2)$ alkylcarbonyl- $(C_1-C_2)$ alkyl, and optionally substituted heterocyclyl selected from pyridyl and thienyl;

and pharmaceutically acceptable salts thereof;

٠٨

provided R<sup>7</sup> is not CF<sub>3</sub> when R<sup>9</sup> is ethoxycarbonyl and when R<sup>8</sup> is 4-pyridyl or 2-chloro-4-pyridyl.

28. (Previously Presented) A Compound of Claim 27 wherein R<sup>7</sup> is selected from methyl, ethyl, propyl, isopropyl, dimethylaminomethyl, 1-pyrrolidinyltheyl, benzyloxymethyl, benzyloxymethyl, benzyloxymethyl, denzyloxymethyl, denzyloxymethyl, methoxymethyl, cyclopropyl and – CF<sub>3</sub>; wherein R<sup>8</sup> is selected from N-methyl-N-(phenylsulfonyl)amino, 2-pyridylsulfonylmethyl, 2-thienylsulfonylmethyl, (1-methyl)-1-(phenylsulfonyl)ethyl, 4-chlorophenyl-sulfonylmethyl, 2-furylmethylsulfonylmethyl, methylsulfonylmethyl, tert-butyl-sulfonylmethyl, 4-fluorobenzylsulfonylmethyl, 2-thienyl, phenyl substituted with one or more substituents selected from

chloro, fluoro, and -O-CH<sub>2</sub>-O-, unsubstituted pyridyl, and

4-pyridyl substituted with one or more substituents selected from chloro, fluoro, -NH<sub>2</sub>, methoxy, ethoxy, methyl, ethyl, phenoxyethylamino, methylamino, butylamino, isobutylamino, dimethylamino, benzylamino, 4-fluorobenzylamino, 2-thienylethylamino, 3-pyridylmethylamino, 2-pyridylmethylamino, 2-furylmethylamino, 4-methoxybenzylamino,

diethylamino, cyclopropylmethylamino, cyclopentylmethylamino, ethylaminoethylamino, diethylaminoethylamino, isopropylaminoethylamino, methylcarbonylaminoethylamino, methylcarbonylmethylamino, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl and azetidinyl; and

. 1.

٠,

wherein R<sup>9</sup> is selected from H, bromo, methyl, hydroxymethyl, 1,2,5,6-tetrahydro-1pyridylmethyl, 1-piperidinylmethyl, 1-methyl-4-piperazinylmethyl, (N-diethylaminoethyl-Nmethyl)aminomethyl, (N-dimethylaminoethyl-N-ethyl)aminomethyl, 4,5-dihydro-oxazol-2yl, 5-methyl-4,5-dihydro-oxazol-2-yl, 2-furyl, amino, isobutylamino, 3-methylbutylamino, ethylcarbonyl, aminocarbonyl, 4-methoxybenzylaminocarbonyl, 2pyridylmethylaminocarbonyl, 4-pyridylmethylaminocarbonyl, dimethylaminocarbonyl, ethylaminoethylaminocarbonyl, isopropylaminoethylaminocarbonyl, cyclopropylmethylaminocarbonyl, isobutylaminocarbonyl, ethoxycarbonyl, propoxycarbonyl, 1-methylpropoxycarbonyl, butoxycarbonyl, iso-butoxycarbonyl, tertbutoxycarbonyl, 2-thienylethoxycarbonyl, 4-morpholinylethoxycarbonyl, (4piperidinyl)methoxycarbonyl, (1-piperidinyl)ethoxycarbonyl, (1-piperazinyl)ethoxycarbonyl, (1-methyl-piperidin-3-yl)oxycarbonyl, (1-methyl-piperidin-4-yl)oxycarbonyl, (1-ethylpiperidin-3-yl)oxycarbonyl, (1-methyl-pyrrolidin-3-yl)oxycarbonyl, 1pyrrolidinylethoxycarbonyl, 2-oxo-pyrrolidin-1-ylethoxycarbonyl, 2-oxo-pyrrolidin-1ylpropoxycarbonyl, 1-methyl-2-pyrrolidinylethoxycarbonyl, 1-piperidinylethoxycarbonyl, diethylaminoethoxycarbonyl, di-isopropylaminoethoxycarbonyl, (N-ethyl-Nbenzylamino)ethoxycarbonyl, diethylaminopropoxycarbonyl, dimethylaminoethoxycarbonyl, 2-(dimethylamino)-1-(methyl)ethoxycarbonyl, 2-(diethylamino)-1-(methyl)ethoxycarbonyl, carboxyl, methylcarbonylamino, isobutylcarbonylamino, methylaminomethylcarbonylamino, dimethylaminomethylcarbonylamino, tert-butylaminomethylcarbonylamino, (1-amino-2methylpropyl)carbonylamino, 1-piperidinylmethylcarbonylamino, 1piperidinylethylcarbonylamino, 1-piperidinylpropylcarbonylamino, aminomethylcarbonylamino and 1-methyl-4-piperazinylcarbonyl; and pharmaceutically acceptable salts thereof.

29. (Previously Presented) A Compound of Claim 27 wherein R<sup>7</sup> is selected from methyl, ethyl, propyl, and isopropyl.

30. (Previously Presented) A Compound of Claim 27 wherein R<sup>8</sup> is selected from phenylsulfonylmethyl and 4-pyridyl substituted with one or more substituents selected from chloro, fluoro, -NH<sub>2</sub>, methoxy, ethoxy, phenoxyethylamino, methylamino, dimethylamino, methyl, ethyl, butylamino, isobutylamino, benzylamino, 4-fluorobenzylamino, 2-thienylethylamino, 3-pyridylmethylamino, 2-pyridylmethylamino, 2-furylmethylamino, 4-methoxybenzylamino, diethylamino, cyclopropylmethylamino, cyclopentylmethylamino, ethylaminoethylamino, diethylaminoethylamino, isopropylaminoethylamino, methylcarbonylaminoethylamino, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl and azetidinyl.

÷ξ

31. (Previously Presented) A Compound of Claim 27 wherein R<sup>9</sup> is selected from methyl, hydroxymethyl, 1,2,5,6-tetrahydro-1-pyridylmethyl, 1-piperidinylmethyl, 1-methyl-4piperazinvlmethyl, (N-diethylaminoethyl-N-methyl)aminomethyl, (N-dimethylaminoethyl-Nethyl)aminomethyl, 4,5-dihydro-oxazol-2-yl, 5-methyl-4,5-dihydro-oxazol-2-yl, 2-furyl, amino, isobutylamino, 3-methylbutylamino, ethylcarbonyl, aminocarbonyl, 4methoxybenzylaminocarbonyl, 2-pyridylmethylaminocarbonyl, 4-pyridylmethylaminocarbonyl, dimethylaminocarbonyl, ethylaminoethylaminocarbonyl, isopropylaminoethylaminocarbonyl, cyclopropylmethylaminocarbonyl, isobutylaminocarbonyl, ethoxycarbonyl, propoxycarbonyl, 1methylpropoxycarbonyl, butoxycarbonyl, iso-butoxycarbonyl, tert-butoxycarbonyl, 2thienylethoxycarbonyl, 4-morpholinylethoxycarbonyl, (4-piperidinyl)methoxycarbonyl, (1piperidinyl)ethoxycarbonyl, (1-piperazinyl)ethoxycarbonyl, (1-methyl-piperidin-3yl)oxycarbonyl, (1-methyl-piperidin-4-yl)oxycarbonyl, (1-ethyl-piperidin-3-yl)oxycarbonyl, (1methyl-pyrrolidin-3-yl)oxycarbonyl, 1-pyrrolidinylethoxycarbonyl, 2-oxo-pyrrolidin-1ylethoxycarbonyl, 2-oxo-pyrrolidin-1-ylpropoxycarbonyl, 1-methyl-2pyrrolidinylethoxycarbonyl, 1-piperidinylethoxycarbonyl, diethylaminoethoxycarbonyl, diisopropylaminoethoxycarbonyl, (N-ethyl-N-benzylamino)ethoxycarbonyl, diethylaminopropoxycarbonyl, dimethylaminoethoxycarbonyl, 2-(dimethylamino)-1-(methyl)ethoxycarbonyl, 2-(diethylamino)-1-(methyl)ethoxycarbonyl, carboxyl, methylcarbonylamino, isobutylcarbonylamino, methylaminomethylcarbonylamino, dimethylaminomethylcarbonylamino, tert-butylaminomethylcarbonylamino, (1-amino-2-

- methylpropyl)carbonylamino, 1-piperidinylmethylcarbonylamino, 1-piperidinylpropylcarbonylamino, aminomethylcarbonylamino and 1-methyl-4-piperazinylcarbonyl; and pharmaceutically acceptable salts thereof.
- 32. (Previously Presented) ACompound of Claim 27 and pharmaceutically acceptable salts thereof selected from:
- 6-Isopropyl-5-methyl-3-(2-pyrindin-4-yl-thiazol-4-yl)-1*H*-pyridin-2-one;

, ?

- 6-Ethyl-5-isopropionyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1*H*-pyridin-2-one;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-(2-oxo-pyrrolidin-1-yl)-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-diethylamino-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-pyrrolidin-1-yl-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-diethylamino-1-methyl-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 1-ethyl-piperidin-3-yl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-dimethylamino-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-dimethylamino-1-methyl-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 1-methyl-piperidin-3-yl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 1-ethyl-pyrrolidin-3-yl ester;
- 5-(2-Benzenesulfonylmethyl-thiazol-4-yl)-2-isopropyl-6-oxo-1,6-pyridine-3-carboxylic acid 2-diethylamino-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid piperidin-4-ylmethyl ester;

5-(2-Benzenesulfonylmethyl-thiazol-4-yl)-2-isopropyl-6-oxo-1,6-pyridine-3-carboxylic acid 2-diethylamino-1-methyl-ethyl ester;

. . .

- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-(benzyl-methyl-amino)-ethyl ester;
- 5-(2-Benzenesulfonylmethyl-thiazol-4-yl)-2-isopropyl-6-oxo-1,6-pyridine-3-carboxylic acid 2-diethylamino-propyl ester;
- 5-(2-Benzenesulfonylmethyl-thiazol-4-yl)-2-isopropyl-6-oxo-1,6-pyridine-3-carboxylic acid 2-(1-methyl-pyrrolidin-2-yl)-ethyl ester;
- 5-[2-(2-Dimethylamino-pyridin-4-yl)-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-piperazin-1-yl-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-(2-oxo-pyrrolidin-1-yl)-propyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 1-methyl-pyrrolidin-3-yl ester;
- 3-(2-Benzenesulfonylmethyl-thiazol-4-yl)-6-isopropyl-5-methyl-1*H*-pyridin-2-one;
- 3-(2-Benzenesulfonylmethyl-thiazol-4yl)-6-ethyl-5-propionyl-1*H*-pyridin-2-one;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-morpholin-4-yl-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid phenethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid piperidin-4-ylmethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-thiophen-2-yl-ethyl ester;
- 5-(4,5-Dihydro-oxazol-2-yl)-6-isopropyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1H-pyridin-2-one;
- 5-{[(2-Dimethylamino-ethyl)-ethyl-amino]-methyl}-6-ethyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1H-pyridin-2-one;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-piperidin-1-yl-ethyl ester;

- 5-{[(2-Diethylamino-ethyl)-methyl-amino]-methyl}-6-ethyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1H-pyridin-2-one;
- 2-(2-Hydroxy-ethyl)-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid ethyl ester;
- 2-Amino-N-[2-ethyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridin-3-yl]-acetamide;
- 2-tert-Butylamino-N-[2-ethyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridin-3-yl]-acetamide;
- 6-Ethyl-5-(3-methyl-butylamino)-3-(2-pyridin-4-yl-thiazol-4-yl)-1H-pyridin-2-one;

. .

- Ethyl 2-ethyl-6-oxo-5-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylate;
- Ethyl-2-ethyl-6-oxo-5-{2-[(thienylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydro-pyridine-3-carboxylate;
- Ethyl-2-ethyl-6-oxo-5-{2-[(phenylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydro-pyridine-3-carboxylate;
- Ethyl-6-oxo-5-{2-[(phenylsulfonyl)methyl](1,3-thiazol-4-yl)}-2-(trifluoromethyl)-1,6-dihydro-pyridine-3-carboxylate;
- Ethyl-6-oxo-5-{2-[(2-pyridylsulfonyl)methyl](1,3-thiazol-4-yl)}-2-(trifluoromethyl)-1,6-dihydro-pyridine-3-carboxylate;
- Ethyl-6-oxo-5-{2-[(2-thienylsulfonyl)methyl](1,3-thiazol-4-yl)}-2-(trifluoromethyl)-1,6-dihydro-pyridine-3-carboxylate;
- Ethyl 2-isopropyl-6-oxo-5-(2-(4-pyridyl)(1,3-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylate;
- Ethyl 2-isopropyl-6-oxo-5-{2-[(thienylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydro-pyridine-3-carboxylate;
- Ethyl 2-isopropyl-6-oxo-5-{2-[(phenylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydro-pyridine-3-carboxylate;
- Ethyl 2-propyl-6-oxo-5-(2-(4-pyridyl)(1,3-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylate;
- Ethyl 2-propyl-6-oxo-5-{2-[(phenylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydro-pyridine-3-carboxylate;
- Ethyl 2-propyl-6-oxo-5-{2-[(thienylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 6-oxo-2-[(phenylmethoxy)methyl]-5-(2-(4-pyridyl)(1,3-thiazol-4-yl))-1,6-dihydropyridine-

3-carboxylate;

. .

- Ethyl 6-oxo-2-[(phenylmethoxy)methyl]-5-{2-[(phenylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-{2-[(2-thienylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-({[(4-fluorophenyl)methyl]sulfonyl}methyl)(1,3-thiazol-4-yl)]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-({[(4-fluorophenyl)methyl]sulfonyl}methyl)(1,3-thiazol-4-yl)]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- (Ethyl 2-methyl-6-oxo-5-{2-[(2-thienylsulfonyl)methyl]methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-{2-(phenylthiomethyl)(1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-(2-chloro(4-pyridyl))(1,3-thiazol-4-yl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-(2-{[(2-furylmethyl)sulfonyl]methyl}(1,3-thiazol-4-yl))-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-(2-{[(2-furylmethyl)sulfonyl]methyl}(1,3-thiazol-4-yl))-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate
- Ethyl 5-[2-(2-ethyl(4-pyridyl))(1,3-thiazol-4-yl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-5-(2-((2-methylpropyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-(2-(2-((3-pyridinylmethyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-(2-(2-((phenylmethyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-5-(2-((2-((1-methylethyl)amino)ethyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-(2-(2-((2-((diethylamino)ethyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;

Ethyl 5-(2-{2-[(fur-2-ylmethyl)-amino]-pyridin-4-yl}-thiazol-4-yl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;

. . . .

- Ethyl 5-{2-[2-(2-thien-2-yl-ethylamino)-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-(2-butylamino-pyridin-4-yl)-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-{2-[2-(carbamoylmethyl-amino)-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-{2-[2-acetylamino-ethylamino)-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- 5-{2-[2-(Cyclopropylmethylamino)-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid cyclopropyl-methyl amide;
- Ethyl 5-{2-[2-(cyclopropylmethyl-amino)-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- 5-{2-[2-(Cyclopentyl)methylamino-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- 5-{2-[2-(4-Methoxybenzylamino)-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 4-methoxy-benzylamide;
- Ethyl 2-methyl-6-oxo-5-(2-(2-amino-4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-5-[2-(methylamino)(1,3-thiazol-4-yl)]-6-oxo-1,6-dihydropyridine-3-carboxylate; 6-Methyl-3-(2-(4-pyridyl)(1,3-thiazol-4-yl))hydropyridin-2-one;
- Ethyl 2-methyl-5-(2-(2-(methyloxy)-4-pyridinyl)-1,3-thiazol-4-yl)-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-{2-[(phenylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-(2-(4-pyridyl)(1,3-thiazol-4-yl))-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-{2-[(2-pyridylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-5-(2-(1-methyl-1-(phenylsulfonyl)ethyl)-1,3-thiazol-4-yl)-6-oxo-1,6-dihydropyridine-3-carboxylate;

- Ethyl 2-cyclopropyl-6-oxo-5-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-cyclopropyl-6-oxo-5-(2-((phenylsulfonyl)methyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- 5-Bromo-6-methyl-3-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-2(1H)-pyridinone;

· 🖫

- Ethyl 2-methyl-5-(2-(2-(methylamino)-4-pyridinyl)-1,3-thiazol-4-yl)-6-oxo-1,6-dihydropyridine-3-carboxylate
- 5-Amino-6-ethyl-3-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-2(1H)-pyridinone;
- 6-Methyl-3-(2-((2-pyridinylmethyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-2(1H)-pyridinone;
- Ethyl 2-methyl-6-oxo-5-(2-(2-((2-pyridinylmethyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-(methylamino-pyridin-4-yl)-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- 1,1-Dimethylethyl 2-methyl-6-oxo-5-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- 2-(1-Pyrrolidinyl)ethyl 2-ethyl-6-oxo-5-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- 6-Ethyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1H-pyridin-2-one;
- 6-Isopropyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1H-pyridin-2-one;
- 3-(Diethylamino)propyl 2-ethyl-6-oxo-5-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- 3-(Diethylamino)propyl 2-(1-methylethyl)-6-oxo-5-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate; and
- 5-Hydroxymethyl-6-methyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1H-pyridin-2-one.
- 33. (Previously Presented) A Compound of Claim 27 and pharmaceutically acceptable salts thereof selected from:
- 6-Isopropyl-5-methyl-3-(2-pyrindin-4-yl-thiazol-4-yl)-1*H*-pyridin-2-one;
- 3-(2-Benzenesulfonylmethyl-thiazol-4-yl)-6-isopropyl-5-methyl-1*H*-pyridin-2-one;
- 6-Ethyl-5-isopropionyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1*H*-pyridin-2-one;

3-(2-Benzenesulfonylmethyl-thiazol-4yl)-6-ethyl-5-propionyl-1*H*-pyridin-2-one;

• 7

- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-pyrrolidin-1-yl-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-(2-oxo-pyrrolidin-1-yl)-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-diethylamino-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 1-ethyl-piperidin-3-yl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 1-methyl-piperidin-3-yl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-dimethylamino-1-methyl-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-diethylamino-1-methyl-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-(benzyl-methyl-amino)-ethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 1-methyl-piperidin-4-yl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-(2-oxo-pyrrolidin-1-yl)-propyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid phenethyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid 2-thiophen-2-yl-ethyl ester;
- 5-(2-Benzenesulfonylmethyl-thiazol-4-yl)-2-isopropyl-6-oxo-1,6-pyridine-3-carboxylic acid 2-diethylamino-ethyl ester;
- 5-(2-Benzenesulfonylmethyl-thiazol-4-yl)-2-isopropyl-6-oxo-1,6-pyridine-3-carboxylic acid 2-diethylamino-1-methyl-ethyl ester;
- 5-(2-Benzenesulfonylmethyl-thiazol-4-yl)-2-isopropyl-6-oxo-1,6-pyridine-3-carboxylic acid 2-diethylamino-propyl ester;

5-(2-Benzenesulfonylmethyl-thiazol-4-yl)-2-isopropyl-6-oxo-1,6-pyridine-3-carboxylic acid 2-(1-methyl-pyrrolidin-2-yl)-ethyl ester;

- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid methyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid propyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid butyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid isobutyl ester;
- 2-Isopropyl-6-oxo-5-(2-pyridin-4-yl-thiazol-4-yl)-1,6-dihydro-pyridine-3-carboxylic acid secbutyl ester;
- 5-{[(2-Diethylamino-ethyl)-methyl-amino]-methyl}-6-ethyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1H-pyridin-2-one;
- 5-[2-(2-Dimethylamino-pyridin-4-yl)-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid ethyl ester;
- Ethyl 2-ethyl-6-oxo-5-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-ethyl-6-oxo-5-{2-[(thienylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-ethyl-6-oxo-5-{2-[(phenylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-isopropyl-6-oxo-5-(2-(4-pyridyl)(1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-isopropyl-6-oxo-5-{2-[(thienylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-isopropyl-6-oxo-5-{2-[(phenylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-propyl-6-oxo-5-(2-(4-pyridyl)(1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-propyl-6-oxo-5-{2-[(phenylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;

- Ethyl 2-propyl-6-oxo-5-{2-[(thienylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 6-oxo-2-[(phenylmethoxy)methyl]-5-(2-(4-pyridyl)(1,3-thiazol-4-yl))-1,6-dihydropyridine-3-carboxylate;
- Ethyl 6-oxo-2-[(phenylmethoxy)methyl]-5-{2-[(phenylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-{2-[(2-thienylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-({[(4-fluorophenyl)methyl]sulfonyl}methyl)(1,3-thiazol-4-yl)]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-({[(4-fluorophenyl)methyl]sulfonyl}methyl)(1,3-thiazol-4-yl)]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-{2-(phenylthiomethyl)(1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-(2-ethyl(4-pyridyl))(1,3-thiazol-4-yl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-(2-chloro(4-pyridyl))(1,3-thiazol-4-yl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-(3,5-Dichloro-pyridin-4-yl)-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-5-(2-(2-((2-methylpropyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-(2-(2-((3-pyridinylmethyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-(2-(2-((phenylmethyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-5-(2-((2-((1-methylethyl)amino)ethyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-(2-((2-((2-((2-((2-((2-(diethylamino)-4-pyridinyl)-1,3-thiazol-4-yl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;

Ethyl 5-(2-{2-[(fur-2-ylmethyl)-amino]-pyridin-4-yl}-thiazol-4-yl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;

- Ethyl 5-{2-[2-(2-thien-2-yl-ethylamino)-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-(2-butylamino-pyridin-4-yl)-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-{2-[2-(carbamoylmethyl-amino)-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-{2-[2-acetylamino-ethylamino)-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- 5-{2-[2-(Cyclopropylmethylamino)-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxohydro-pyridine-3-carboxylic acid cyclopropyl-methyl amide;
- Ethyl 5-{2-[2-(cyclopropylmethyl-amino)-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-{2-[2-(cyclopentyl)methylamino-pyridin-4-yl]-thiazol-4-yl}-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-(2-(2-(amino)-4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-5-[2-(methylamino)(1,3-thiazol-4-yl)]-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-{2-[(phenylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-(2-(4-pyridyl)(1,3-thiazol-4-yl))-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-6-oxo-5-{2-[(2-pyridylsulfonyl)methyl](1,3-thiazol-4-yl)}-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-methyl-5-(2-(1-methyl-1-(phenylsulfonyl)ethyl)-1,3-thiazol-4-yl)-6-oxo-1,6-dihydropyridine-3-carboxylate;
- Ethyl 2-cyclopropyl-6-oxo-5-(2-((phenylsulfonyl)methyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- 5-Bromo-6-methyl-3-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-2(1H)-pyridinone;
- Ethyl 2-methyl-5-(2-(2-(methylamino)-4-pyridinyl)-1,3-thiazol-4-yl)-6-oxo-1,6-dihydropyridine-3-carboxylate;

- 2-Methyl-6-oxo-N-(2-pyridinylmethyl)-5-(2-(2-((2-pyridinylmethyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxamide;
- Ethyl 2-methyl-6-oxo-5-(2-(2-((2-pyridinylmethyl)amino)-4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- Ethyl 5-[2-(methylamino-pyridin-4-yl)-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate;
- 1,1-Dimethylethyl 2-methyl-6-oxo-5-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- 2-(1-Pyrrolidinyl)ethyl 2-ethyl-6-oxo-5-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate;
- 6-Ethyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1H-pyridin-2-one;
- 6-Isopropyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1H-pyridin-2-one;
- 3-(Diethylamino)propyl 2-ethyl-6-oxo-5-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate; and
- 3-(Diethylamino)propyl 2-(1-methylethyl)-6-oxo-5-(2-(4-pyridinyl)-1,3-thiazol-4-yl)-1,6-dihydropyridine-3-carboxylate.
- 34. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.
- 35-39 (Cancelled).